Comparative Efficacy of Dienogest and Cabergoline in Pain Relief and Size Reduction of Ovarian Endometriomas: A Prospective Study
article
OA: green
CC0
Abstract
ABSTRACT: Endometriosis is a condition in which the growth of endometrial tissue occurs outside its typical location (most frequently the ovaries, where endometriomas form). This disease is the main reason for chronic pelvic pain and infertility in women of reproductive age. In this prospective comparative study, 50 women with ultrasound-detected ovarian endometriomas and pelvic pain were enrolled. They were randomly assigned to receive cabergoline 0.5 mg twice a week or dienogest 2 mg once a day for three months. The primary outcomes were changes in endometrioma size and pain scores. After the treatment, dienogest reduced the mean cyst diameter to a greater extent (around 19.7% compared to 8.77% with cabergoline), while cabergoline resulted in a slightly higher average reduction in visual analog scale pain scores (73% compared to 65% with dienogest), but this difference was not statistically significant. Both treatment regimens were generally well tolerated, with only mild and transient adverse effects reported. The results indicate that dienogest could be the drug of choice if the main therapeutic goal is to shrink the endometrioma, whereas cabergoline might be the drug of choice if pain relief and fertility preservation are prioritized. Therefore, larger and longer-term studies are needed to verify these observations.
Full text
1,984 characters
· extracted from
oa-doi-fallback
· click to expand
Comparative Efficacy of Dienogest and Cabergoline in Pain Relief and Size Reduction of Ovarian Endometriomas: A Prospective Study
Authors/Creators
- 1. Department of Obstetrics and Gynaecology, Murshidabad Medical College and Hospital, Berhampore, West Bengal, India
- 2. Department of EIE, Techno Main Salt Lake, Kolkata, West Bengal, India
- 3. Department of AEIE, Heritage Institute of Technology, Kolkata, West Bengal, India
Description
ABSTRACT: Endometriosis is a condition in which the growth of endometrial tissue occurs outside its typical location (most frequently the ovaries, where endometriomas form). This disease is the main reason for chronic pelvic pain and infertility in women of reproductive age. In this prospective comparative study, 50 women with ultrasound-detected ovarian endometriomas and pelvic pain were enrolled. They were randomly assigned to receive cabergoline 0.5 mg twice a week or dienogest 2 mg once a day for three months. The primary outcomes were changes in endometrioma size and pain scores. After the treatment, dienogest reduced the mean cyst diameter to a greater extent (around 19.7% compared to 8.77% with cabergoline), while cabergoline resulted in a slightly higher average reduction in visual analog scale pain scores (73% compared to 65% with dienogest), but this difference was not statistically significant. Both treatment regimens were generally well tolerated, with only mild and transient adverse effects reported. The results indicate that dienogest could be the drug of choice if the main therapeutic goal is to shrink the endometrioma, whereas cabergoline might be the drug of choice if pain relief and fertility preservation are prioritized. Therefore, larger and longer-term studies are needed to verify these observations.
Files
06Rajar.pdf
Files
(362.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:38b20f622d6a911b022542cbe6e1bd8a
|
362.3 kB | Preview Download |
Additional details
Dates
- Available
-
2025-12-15
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK